What is Noze?
Noze is revolutionizing medical diagnostics with its proprietary digital nose technology, designed to detect diseases by analyzing volatile organic compounds (VOCs) emitted through breath and skin. The company's flagship product, DiagNoze, is currently under development and aims to provide real-time health assessments at various points of care. By integrating advanced scent detection into everyday applications, Noze targets critical sectors including healthcare, safety, and food integrity, with the ultimate goal of improving global health outcomes and quality of life.
How much funding has Noze raised?
Noze has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2024): $5M with participation from Bill & Melinda Gates Foundation
Key Investors in Noze
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, a prominent global health organization, focuses on improving health outcomes and reducing poverty worldwide, aligning with Noze's mission to enhance disease detection and healthcare diagnostics.
What's next for Noze?
This substantial enterprise-level backing positions Noze for accelerated growth and the scaling of its groundbreaking DiagNoze technology. The strategic investment signals strong confidence from major stakeholders in Noze's mission to transform disease detection. Future developments are expected to focus on clinical validation, regulatory approvals, and the commercialization of its digital nose solutions, potentially establishing new standards in non-invasive diagnostics and health monitoring.
See full Noze company page
